<?xml version="1.0" encoding="UTF-8"?>
<p id="Par56">On April 9, 2020, the National Institute for Health and Care Excellence (NICE) published a series of recommendations to be adopted during the current COVID-19 pandemic for patients with skin diseases, including eczema, who carry out immunomodulatory therapies [
 <xref ref-type="bibr" rid="CR26">26</xref>]. There is no data that Dupilumab can somehow increase the risk of SARS-CoV-2 infection, and it can also be done subcutaneously at home. Starting a new therapy with Dupilumab should be considered with extreme caution, while it is advisable to continue an ongoing therapy [
 <xref ref-type="bibr" rid="CR27">27</xref>, 
 <xref ref-type="bibr" rid="CR28">28</xref>] regularly. The British Association of Dermatologists has provided a grid for healthcare professionals to identify patients for whom COVID-19 poses a higher risk due to their disease and treatment. Interruption of drug therapy should only be done on the advice of the attending physician, who decide on an individual basis [
 <xref ref-type="bibr" rid="CR29">29</xref>].
</p>
